The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 22 of those trials with a site in Advanced Solid Tumors.
22 of the 2,500 most recently authorised trials in this register list a site in Advanced Solid Tumors; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase I | 15 | 68.2% |
| Phase I/II | 7 | 31.8% |
| Lead sponsor | Trials |
|---|---|
| Pfizer Inc. | 3 |
| Bristol-Myers Squibb Services Unlimited Company | 2 |
| AstraZeneca AB | 1 |
| BeOne Medicines I GmbH | 1 |
| BioNTech SE | 1 |
| Daiichi Sankyo Inc. | 1 |
| Eikon Therapeutics Inc. | 1 |
| F. Hoffmann-La Roche AG | 1 |
| Gilead Sciences Inc. | 1 |
| Janssen Cilag International | 1 |